Voluntis and AstraZeneca have extended their partnership to evaluate a mobile app, called eCO (eCediranib/Olaparib), to help women with platinum-resistant ovarian cancer report and manage their side effects. The approach is being developed for women receiving a combination of cediranib plus Lynparza (olaparib), and will be tested in the GY005 Phase 2/3 clinical trial (NCT02502266), which started in 2015 and is sponsored by the National Cancer Institute (NCI). The study aims to evaluate the efficacy of cediranib and Lynparza, given alone or in combination, in fighting cancers in the ovaries, fallopian tube, or peritoneum, a membrane lining the abdominal cavity and covering the abdominal organs. Lynparza, by AstraZeneca, works by preventing cancer cells from repairing damaged DNA, which causes them to die. The medicine is approved for ovarian cancer patients who responded to prior platinum-based chemotherapy, or for those with BRCA mutations who received three or more prior chemotherapies. Cediranib, also by AstraZeneca, is being developed to block the formation of new blood vessels required for a tumor to grow. Only patients whose disease did not respond to platinum-based chemotherapy or stopped responding to such medications will be admitted in the study.